The natural history of multiple sclerosis
- PMID: 3311324
- DOI: 10.1017/s0317167100026573
The natural history of multiple sclerosis
Abstract
Studies which have attempted to define the outcome of multiple sclerosis (MS) have methodologic difficulties arising from patient referral biases and the length of follow-up required, which make prospective studies of an inception cohort unrealistic. Means to improve the validity of retrospective natural history studies are suggested. Results of existing series are summarized and compared. Survival is only rarely shortened by MS, but disability to the point of requiring aids for ambulation occurs in 30-70% of patients by 15 years from onset of symptoms. Disagreement as to the percentage of patients who are ultimately bedridden by MS likely arises in large part due to differences in patient ascertainment and follow-up. The need to develop early clinical markers for the patient at high risk for rapid development of major disability is stressed.
Similar articles
-
The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.Brain. 1989 Dec;112 ( Pt 6):1419-28. doi: 10.1093/brain/112.6.1419. Brain. 1989. PMID: 2597989
-
The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.Brain. 1989 Feb;112 ( Pt 1):133-46. doi: 10.1093/brain/112.1.133. Brain. 1989. PMID: 2917275
-
The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis.Brain. 1999 Apr;122 ( Pt 4):625-39. doi: 10.1093/brain/122.4.625. Brain. 1999. PMID: 10219776
-
The natural history of multiple sclerosis.Neurol Clin. 1995 Feb;13(1):119-46. Neurol Clin. 1995. PMID: 7739500 Review.
-
Natural history of multiple sclerosis: long-term prognostic factors.Neurol Clin. 2011 May;29(2):293-308. doi: 10.1016/j.ncl.2011.01.006. Neurol Clin. 2011. PMID: 21439442 Review.
Cited by
-
Are current immunological concepts of multiple sclerosis reflected by the immunopathology of its lesions?Springer Semin Immunopathol. 1995;17(1):77-87. doi: 10.1007/BF00194101. Springer Semin Immunopathol. 1995. PMID: 7482228 Review.
-
Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.J Neurol. 2005 Jul;252(7):795-800. doi: 10.1007/s00415-005-0748-5. Epub 2005 Mar 18. J Neurol. 2005. PMID: 15772741 Clinical Trial.
-
Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death.J Neuroinflammation. 2010 Apr 13;7:25. doi: 10.1186/1742-2094-7-25. J Neuroinflammation. 2010. PMID: 20388219 Free PMC article.
-
Clinical prognostic factors in multiple sclerosis: a natural history review.Nat Rev Neurol. 2009 Dec;5(12):672-82. doi: 10.1038/nrneurol.2009.178. Nat Rev Neurol. 2009. PMID: 19953117 Review.
-
[MS registry in Germany--design and first results of the pilot phase].Nervenarzt. 2005 Aug;76(8):967-75. doi: 10.1007/s00115-005-1907-8. Nervenarzt. 2005. PMID: 15806419 Clinical Trial. German.
Publication types
MeSH terms
LinkOut - more resources
Medical